References
- Tibes R, Mesa RA. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? Leuk. Lymphoma 52(7), 1178–1187 (2011).
- Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366(9), 799–807 (2012).
- Verstovsek S, Kantarjian HM, Estrov Z et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6), 1202–1209 (2012).
- Harrison C, Kiladjian JJ, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366(9), 787–798 (2012).
- Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N. Engl. J. Med. 365(15), 1455–1457 (2011).
- Tibes R, Bogenberger JM, Geyer HL, Mesa RA. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin. Investig. Drugs (2012) (In Press).
- Tibes R, Mesa RA. Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques. Leuk. Res. 36(6), 664–671 (2012).
- Verstovsek S, Mesa RA, Rhoades SK et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). ASH Annual Meeting Abstracts 118(21), 2814 (2011).
- Pardanani A, Gotlib JR, Jamieson C et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol. 29(7), 789–796 (2011).
- Beer PA, Delhommeau F, LeCouédic JP et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115(14), 2891–2900 (2010).
- Bogani C, Ponziani V, Guglielmelli P et al.; Myeloproliferative Disorders Research Consortium. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 26(8), 1920–1930 (2008).
- Wang X, Zhang W, Ishii T et al. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res. 69(19), 7612–7618 (2009).
- Scherber R, Dueck AC, Johansson P et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118(2), 401–408 (2011).
- Tibes R, Mesa RA. Blood consult: resistant and progressive essential thrombocythemia. Blood 118(2), 240–242 (2011).
- Verstovsek S. Waltzman RJ, Sandor V et al. Response: a randomized, open label, Phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU). J. Clin. Oncol. 29(Suppl.), Abstract TPS203 (2011).